GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Phase 2

Eloralintide

LY3841136

Company
Eli Lilly
Mechanism
mono amylin
Route
Injectable
Recruiting trials
12 recruiting
20.1% Absolute change weight loss · 48 weeks · Adults with obesity or overweight and at least one weight-related comorbidity, without type 2 diabetes · Phase 2 obesity trial

Next milestone: Phase 3 initiation (2026-H1, estimated)

Find a Clinical Trial Near Me

12 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for Eloralintide and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06143956

    A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

    Not yet reported Eli Lilly and Company 1481 participants Est. completion 2028-02 56 sites Mixed
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Recruiting NCT NCT07215559

    A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

    Not yet reported Eli Lilly and Company 200 participants Est. completion 2027-05 42 sites Stand-alone
    Type 2 diabetes Other conditions: Obesity, Overweight
    View official trial listing →
  • Recruiting NCT NCT07282600

    A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

    Not yet reported Eli Lilly and Company 1035 participants Est. completion 2028-02 157 sites Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Recruiting NCT NCT07321886

    A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

    Not yet reported Eli Lilly and Company 1980 participants Est. completion 2030-07 162 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Recruiting NCT NCT07353931

    Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

    Not yet reported Eli Lilly and Company 900 participants Est. completion 2028-05 152 sites Stand-alone
    Osteoarthritis Other conditions: Overweight or Obesity
    View official trial listing →
  • Recruiting NCT NCT07369011

    A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

    Not yet reported Eli Lilly and Company 800 participants Est. completion 2028-04 115 sites Stand-alone
    Other conditions: Sleep Apnea, Obstructive, Obesity, Overweight
    View official trial listing →
  • Recruiting NCT NCT07392190

    A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

    Not yet reported Eli Lilly and Company 900 participants Est. completion 2028-07 187 sites Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Recruiting NCT NCT07401862

    A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.

    Not yet reported Eli Lilly and Company 36 participants Est. completion 2027-03 3 sites Stand-alone
    Other conditions: Hepatic Insufficiency
    View official trial listing →
  • Recruiting NCT NCT07589608

    A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

    Not yet reported Eli Lilly and Company 400 participants Est. completion 2028-02 40 sites Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Recruiting NCT NCT07665879

    A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity

    Not yet reported Eli Lilly and Company 115 participants Est. completion 2027-08 2 sites Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Recruiting NCT NCT07701083

    A Study of Eloralintide (LY3841136) in Healthy Participants

    Not yet reported Eli Lilly and Company 58 participants Est. completion 2026-10 2 sites Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Recruiting NCT NCT07738614

    A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight

    Not yet reported Eli Lilly and Company 56 participants Est. completion 2026-12 2 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT05295940

    A Study of LY3841136 in Healthy and Overweight Participants

    Not yet reported Eli Lilly and Company 148 participants Est. completion 2024-01-25 3 sites Stand-alone
    Other conditions: Obesity, Healthy
    View official trial listing →
  • Completed NCT NCT06230523

    A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

    Not yet reported Eli Lilly and Company 263 participants Est. completion 2025-08-14 43 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT06297616

    A Study of LY3841136 in Japanese Participants With Obesity or Overweight

    Not yet reported Eli Lilly and Company 128 participants Est. completion 2025-11-21 3 sites Mixed
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT06345066

    A Study of LY3841136 in Overweight and Obese Participants

    Not yet reported Eli Lilly and Company 96 participants Est. completion 2025-09-29 3 sites Added to GLP-1
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Active, not recruiting NCT NCT06603571

    A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

    Not yet reported Eli Lilly and Company 367 participants Est. completion 2026-08 52 sites Mixed
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT06916065

    A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity

    Not yet reported Eli Lilly and Company 188 participants Est. completion 2026-01-19 3 sites Mixed
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Completed NCT NCT06916091

    A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight

    Not yet reported Eli Lilly and Company 30 participants Est. completion 2025-09-09 1 site Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Active, not recruiting NCT NCT07426380

    A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function

    Not yet reported Eli Lilly and Company 28 participants Est. completion 2026-10 2 sites Stand-alone
    Other conditions: Kidney Disease, Renal Insufficiency Chronic, Kidney Failure, Chronic, Renal Impairment, Renal Insufficiency, End Stage Kidney Disease
    View official trial listing →
  • Not yet recruiting NCT NCT07765511

    A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes

    Not yet reported Eli Lilly and Company 60 participants Est. completion 2027-06 3 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Not yet recruiting NCT NCT07808060

    A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight

    Not yet reported Eli Lilly and Company 34 participants Est. completion 2027-06 2 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
Efficacy history
20.1%

Absolute change weight loss · 48 weeks

Adults with obesity or overweight and at least one weight-related comorbidity, without type 2 diabetes

Trial: Phase 2 obesity trial (Phase 2)

Source →

Results from different trials are not directly comparable — populations, timepoints, and measurement methods differ between studies.

Safety

Most common adverse events were mild-to-moderate nausea and fatigue; treatment was also associated with improvements in waist circumference, blood pressure, and lipid profile.

Source →
Sources

Also known as: Eloralintide, LY3841136

Related On The Pen coverage

Latest stories

The Weekly Dose & livestreams

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.